<DOC>
	<DOCNO>NCT02634294</DOCNO>
	<brief_summary>Aim : observe graft versus tumor effect Pegylated Interferonα-2b patient hematological malignancy relapse allogeneic hematopoietic stem cell transplantation ( alloHSCT ) Patients : patient relapse alloHSCT , men woman age 14-60 year , without vital organ dysfunction ongoing graft-verus-host disease ( GVHD ) . Number subject : 50 , Single center , one group , prospective . Drug : pegylated interferon alpha-2b ( Peg Intron® ; Schering-Plough ) 1~1.5ug/kg qw , occurrence grade II high grade acute GVHD , response treatment 8 dose treatment .</brief_summary>
	<brief_title>Peg Interferon α-2b Relapsed Hematological Malignancies After Allo-HSCT</brief_title>
	<detailed_description>Eligible patient age 14 60 year molecular , hematological radiography relapse hematological malignancy post allogeneic hematopoietic stem cell transplantation . Molecular relapse define reappearance 1 log increase molecular marker decrease donor chimerism 5 % ; Hematological relapse define reappearance blast bone marrow smear 5 % ; radiography relapse define enlargement lymph node 25 % infiltration tumor cell site . Patients exclude need immunosuppressant treatment ongoing grade II～IV acute GVHD moderate severe chronic GVHD . Eligible patient treat pegylated interferon alpha-2b ( Peg Intron® ; Schering-Plough ( Brinny ) Company , Innishannon , County Cork , Ireland ) 1~1.5ug/kg qw , occurrence grade II high grade acute GVHD , response treatment 8 dose treatment . Patients follow every week . Physical exams blood test include complete blood count ( CBC ) , chemical perform every week . Disease status evaluation perform every month . Number subject : 50 Single center , one group , prospective .</detailed_description>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Hematologic Neoplasms</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<criteria>1 . Age 1460 year , male female 2 . AlloHSCT recipient malignant hematological disease 3 . Disease relapse alloHSCT , include hematological relapse , molecular relapse 4 . Able provide write informed consent comply study procedures 1 . Pregnant nursing woman 2 . Cardiac ejection factor &lt; normal low limit 3 . Active acute chronic GVHD immunosuppressant treatment 4 . Known hypersensitivity allergy interferon 5 . Patient might develop serious complication accord investigator 's experience 6 . Patient undergoing experimental medication</criteria>
	<gender>All</gender>
	<minimum_age>14 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Hematological Neoplasms</keyword>
	<keyword>recurrence</keyword>
	<keyword>Hematopoietic Stem Cell Transplantation</keyword>
	<keyword>peginterferon alfa-2b</keyword>
	<keyword>Graft v Host Disease</keyword>
</DOC>